radiotherapy planning products ישראל - עברית - Ministry of Health

radiotherapy planning products

פיליפס אלקטרוניקס (ישראל) בע"מ - רופא - ציוד תיכנון טיפול ברדיו

radiotherapy products ישראל - עברית - Ministry of Health

radiotherapy products

lavi industrial & medical agencies ltd. - רופא - ציוד לקיבוע הגוף והגנתו מפני קרינה רדיואקטיבית

Immobilization Devices for Radiotherapy ישראל - עברית - Ministry of Health

immobilization devices for radiotherapy

אי.אס.אי. מכשור מדעי לישראל בע"מ - מומחה

סנדוסטטין 30 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 30 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  20 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 20 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  10 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 10 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Episil ® ישראל - עברית - Ministry of Health

episil ®

perrigo israel agencies ltd - כלל האוכלוסיה - gives relief of pain via mechanical barrier action by a protective film that forms in situ and adheres to the oromucosal surface. intended use of episil® includes oral mucositis that may be caused by chemotherapy or radiotherapy

סנדוסטטין   0.1 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.1 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

סנדוסטטין   0.2 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.2 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.2 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.